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Introduction
D-type cyclins are a family of key cell cycle regulators, as they 
are the regulatory subunits of cyclin-dependent kinase 4 and 6 
(CDK4, CDK6), which phosphorylate the pRb family of pro-
teins that are critical substrates for cell cycle progression.1-4 The 
highly conserved sequence among these three members of the 
D-type cyclin family suggests that they have functionally redun-
dant roles, but each member is expressed in a tissue-specific man-
ner.5,6 Consistent with their role in promoting growth, abnormal 
levels of D-type cyclins have been implicated in the develop-
ment of various types of human tumors. The rearrangement 
and/or amplification of the cyclin D1 gene has been reported 
in a wide range of human cancers, including carcinoma of the 
uterine cervix, breast carcinomas and head and neck squamous 
cell carcinomas.7-9 Similarly, abnormalities in the cyclin D2 
gene have also been observed in testicular tumors10,11 and B-cell 
malignancies.12 Moreover, overexpression of cyclin D3 has been 
found in several human cancers,13-16 such as malignancies of the 
thymus.17
We have previously demonstrated that ras-mediated skin tumorigenesis depends on signaling pathways that act 
preferentially through cyclin  D1 and D2. Interestingly, the expression of cyclin  D3 inhibits skin tumor development, 
an observation that conflicts with the oncogenic role of D-type cyclins in the mouse epidermis. Here, we show that 
simultaneous up and downregulation of particular members of the D-type cyclin family is a valuable approach to reduce 
skin tumorigenesis. We developed the K5D3/cyclin  D1-/- compound mouse, which overexpresses cyclin  D3 but lacks 
expression of cyclin D1 in the skin. Similar to K5D3 transgenic mice, keratinocytes from K5D3/cyclin D1-/- compound mice 
show a significant reduction of cyclin  D2 levels. therefore, this model allows us to determine the effect of cyclin  D3 
expression when combined with reduced or absent expression of the remaining two members of the D-type cyclin family 
in mouse epidermis. our data show that induced expression of cyclin D3 compensates for the reduced level of cyclin D1 
and D2, resulting in normal keratinocyte proliferation. However, simultaneous ablation of cyclin D1 and downregulation 
of cyclin D2 via cyclin D3 expression resulted in a robust reduction in ras-mediated skin tumorigenesis. We conclude that 
modulation of the levels of particular members of the D-type cyclin family could be useful to inhibit tumor development 
and, in particular, ras-mediated tumorigenesis.
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In addition to its growth-promoting functions, cyclin D3 
plays a unique, nonredundant and tissue-specific role in muscle 
differentiation18,19 as well as during advanced stages of differen-
tiation in the epithelia of the stomach, intestine and gallbladder.20
In recent years, our group as well as other investigators have 
utilized the mouse skin model to investigate the role of D-type 
cyclins in normal and neoplastic proliferation.21-25 These stud-
ies established that cyclin D1 and D2 are upregulated in mouse 
skin papillomas and squamous cell carcinomas (SCC), whereas 
cyclin D3 protein levels remain constant in both normal epider-
mis and tumors.21 Supporting these observations, forced expres-
sion of either cyclin D1 or cyclin D2 in mouse epidermis induces 
skin papillomas and SCC, whereas genetic ablation of cyclin D1 
and cyclin D2 reduce tumor development.21-23,26-29 In contrast, 
the forced expression of cyclin D3 inhibits skin tumorigenesis, 
an effect that is mediated by the simultaneous downregulation 
of cyclin D2.29
In this paper, we tested the hypothesis that the simultane-
ous up- and downregulation of individual D-type cyclins is a 
valuable approach to inhibit skin tumorigenesis. We used the 
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12-O-tetradecanoylphorbol-13-acetate (TPA). This stimulus 
induces hyperproliferation that promotes the generation of benign 
tumors (the so-called “papillomas”).
We generated K5D3/cyclin D1-/- mice, which overexpress 
cyclin D3 but lack cyclin D1 expression in skin. Similar to K5D3 
transgenic mice, biochemical analysis of K5D3/cyclin D1-/- epi-
dermis shows a robust reduction of cyclin D2 levels. Therefore, 
this compound mouse model allows us to determine the effect 
of cyclin D3 expression with reduced or absent expression of the 
remaining two members of the D-type cyclin family. Notably, 
the overexpression of cyclin D3 and the simultaneous ablation of 
cyclin D1 led to a robust inhibition of ras-dependent skin tumor-
igenesis, with no effect in normal keratinocyte proliferation and 
differentiation. We conclude that expression of cyclin D3 com-
bined with minimal or absent expression of cyclin D1/D2 is suf-
ficient to support epidermis homeostasis but not ras-mediated 
tumor development. Moreover, our results provide genetic evi-
dence that individual modulation of D-type cyclin levels could 
be a useful method to inhibit ras-mediated tumorigenesis.
Results
Generation and skin characterization of K5D3/cyclin D1-/- 
compound transgenic mice. We have recently reported the gen-
eration of a transgenic mouse (K5D3) wherein the constitutive 
expression of cyclin D3 was targeted to the basal cell layer of the 
epidermis by the 5' regulatory sequence of the bovine keratin 5 
(K5) gene.30 Notably, the epidermis of the K5D3 transgenic mice 
revealed a significant decrease of cyclin D2 expression and con-
comitant reduction of the number of chemically induced skin 
papillomas.29 We also established that cyclin D1-/- mice display 
a 75% reduction in the number of skin papillomas.31 Therefore, 
to study the effect of a simultaneous reduction of both cyclin D1 
and cyclin D2 in keratinocyte proliferation and skin tumorigen-
esis, we generated a K5D3/cyclin D1-/- compound mouse. Similar 
to cyclin D1-/- mice, K5D3/cyclin D1-/- mice show growth retar-
dation and a neurological abnormality evidenced by limb retrac-
tion when lifted by their tails that is most pronounced by three 
weeks.32,33 To determine whether forced expression of cyclin D3 
also results in cyclin D2 downregulation in the cyclin D1-/- 
background, we performed a biochemical analysis of epider-
mal extracts from K5D3, cyclin D1-/-, K5D3/cyclin D1-/- and 
wild-type mice. As expected, cyclin D3 protein levels increased 
6- to 8-fold in the K5D3 and K5D3/cyclinD1-/- epidermis com-
pared with their wild-type siblings (Fig. 1A). Similar to K5D3 
mouse, K5D3/cyclin D1-/- epidermis showed 30-fold reduction in 
cyclin D2 protein levels compared with wild-type mice (Fig. 1A). 
Notably, cyclin D1-null epidermis does not show compensatory 
changes in cyclin D2 and cyclin D3 protein levels (Fig. 1A). 
Additionally, the D-type cyclin partners CDK4 and CDK6 show 
no changes in protein level among the four genotypes analyzed.
To determine whether variation in D-type cyclin levels affect 
the kinase activity of CDKs in mouse keratinocytes, we evalu-
ated the CDK4 and CDK2 kinase activities in epidermal lysates 
from wild-type, K5D3, cyclin D1-/- and K5D3/cyclin D1-/- mice. 
The overexpression of cyclin D3 in the epidermis showed 2-fold 
two-stage mouse skin carcinogenesis protocol, which is a model 
well-suited for understanding the multistage nature of tumor 
progression. In this model, tumor initiation is accomplished 
through a single topical application of a carcinogen, typically 
7,12-dimethylbenz(a)anthracene (DMBA). This produces 
an inheritable genetic mutation in the Ha-ras oncogene, and 
tumor promotion occurs when the initiated cells are expanded 
as a result of multiple applications of a tumor promoter, usually 
Figure 1. Protein gel blot analysis of cell cycle proteins from mouse 
epidermis. (A) Protein lysates of epidermis samples from wild-type (wt), 
K5D3, cyclin D1-/- (D1-/-) and K5D3/D1-/- siblings were separated using 
sodium dodecyl sulfate-PAGe and blotted onto a nitrocellulose mem-
brane. Primary antibodies against cyclin D1, cyclin D2, cyclin D3, CDK4 
and CDK6 were used for immunoblot analysis. β-actin was used as the 
loading control. A vertical line was depicted to note rearrangements 
of the lines in order to be consistent between (A and B). (B) Kinase 
activity of CDK4 and CDK2 from wild-type (wt), K5D3, cyclin D1-/- (D1-/-) 
and K5D3/D1-/- epidermis. Fresh epidermal lysates were immunopre-
cipitated with specific antibodies against CDK4 and CDK2, and in vitro 
kinase assays were performed with prb or Histone H1 (H1) peptides as 
substrates. No Ab, immunoprecipitated with normal IgG; No Sub, no 
substrate were used during the kinase reaction. Protein gel blot analysis 
of the immunoprecipitated with antibodies against CDK4 and CDK2 
serve as control for the efficiency of the immunoprecipitations. A verti-
cal line was depicted in blots of (A and B) to denote rearrangements of 
the lines in order to be consistent between the parts.
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We next asked whether the simultaneous ablation of cyclin D1 
and the reduction of cyclin D2 affect epidermal homeostasis. 
To this end, we examined formalin-fixed, paraffin-embedded 
skin cross-sections of K5D3/cyclin D1-/-, cyclin D1-/-, K5D3 
and wild-type siblings. The gross histological appearance of the 
cyclin D1-/- epidermis revealed a mild hypoplasia, although it 
was not statistically significant (Fig. 2). Hematoxylin and Eosin 
(H&E)-stained sections showed that both K5D3 and K5D3/
cyclin D1-/- epidermis exhibit increased thickness associated with 
an increased number of keratinocytes compared with wild-type 
samples (Fig. 2) (1.8-fold increase; p = 0.0015, t-test). In addi-
tion, we did not observe any obvious alterations in the morphol-
ogy of the follicular and interfollicular epidermis between K5D3 
and K5D3/cyclin D1-/- littermates (Fig. 2). Thus, the expression 
of cyclin D3 appears to be sufficient to compensate for the lack 
of cyclin D1 and the severe downregulation of cyclin D2 in the 
K5D3/cyclin D1-/- mouse epidermis. To determine whether the 
mild hyperplasia observed in K5D3/cyclin D1-/- is a result of 
increase in CDK4 kinase activity compared with wild-type 
siblings. These data are consistent with our previous report, 
which demonstrated that the overexpression of cyclin D3 acti-
vates CDK4 and CDK6 to compensate for the reduced levels of 
cyclin D2 29 (Fig. 1B). Cyclin D1 ablation did not affect CDK4 
kinase activity in mouse keratinocytes, but it did reduce CDK2 
kinase activity by 2-fold compared with wild-type mice (Fig. 1B). 
Consistent with these results, our group and others have shown 
that elevated levels of D-type cyclin/CDK4 complexes bind 
and sequester p27Kip1/p21Cip1 with the consequent activation of 
CDK2.34,35 Therefore, we hypothesize that lack of cyclin D1 
leads to the release of p27Kip1/p21Cip1 from CDK4,6 complexes, 
which, in turn, bind and inhibit CDK2 activity. Together, these 
results show that the K5D3/cyclin D1-/- mouse model represents 
a unique tool to investigate the effects of the simultaneous reduc-
tion of cyclin D1 and D2 levels in keratinocyte proliferation and 
skin tumor development.
Figure 2. Skin phenotype of K5D3/cyclin D1-/- compound mice. (A) representative paraffin-sections of skin from wild-type (wt), D1-/-, K5D3 and 
K5D3/ D1-/- siblings were stained with H&e. (B) Quantification of the total number of epithelial cells in the interfollicular epidermis of the four geno-
types analyzed. (C) BrdU immunostaining of wild-type (wt), D1-/-, K5D3 and K5D3/D1-/- paraffin-sections. Arrows indicate BrdU-positive cells. (D) the 
BrdU label index of the interfollicular epidermis of the four genotypes analyzed.
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levels. We have previously reported that 
cyclin D1- and cyclin D2-knockout 
mice display a significantly reduced 
sensitivity to the development of papil-
lomas induced by chemical carcinogen-
esis.29,31 Similarly, transgenic expression 
of cyclin D3 also decreased skin tumori-
genesis as a result of cyclin D2 down-
regulation.29 Therefore, we next asked 
whether simultaneous reduction of 
cyclin D1 and cyclin D2 would poten-
tiate the tumor inhibition observed in 
cyclin D1-/- and cyclin D2-/- mice.29,31 To 
test this idea, K5D3/cyclin D1-/- mice 
and control littermates were subjected 
to the two-stage carcinogenesis protocol. 
This protocol induces skin papillomas 
after a single application of a carcinogen 
followed by biweekly treatments with 
a tumor promoter that favors the selec-
tion of cells bearing Ha-ras mutations. 
The dorsal skin of K5D3/cyclin D1-/-, 
cyclin D1-/-, K5D3 and wild-type lit-
termates was topically treated with a 
subcarcinogenic dose of the genotoxic 
DMBA, and tumorigenesis was subse-
quently promoted via biweekly applica-
tions of TPA for 25 weeks. The incidence 
and multiplicity of papillomas were 
scored in each group for 24–30 weeks. 
As previously reported in reference 29, 
after 24 weeks of promotion, K5D3 mice 
displayed a significantly lower number 
of tumors per mouse compared with 
wild-type mice (45% reduction, p = 
0.03, t-test) (Fig. 3A). Consistent with 
our previous data, papilloma multiplic-
ity in cyclin D1-/- animals was 18% of 
the quantity observed in the wild-type 
cohort at the same week (p = 0.0003, 
t-test). Notably, the average number 
of tumors per mouse was significantly 
reduced in the K5D3/cyclin D1-/- group (6.5% compared with 
wild-type mice and 36% compared with cyclin D1-/- mice) (Fig. 
3A). Furthermore, when the experiment was extended to 30 
weeks, cyclin D1-/- mice reached a total number of 4.5 papillo-
mas per mouse, whereas K5D3/cyclin D1-/- barely showed 1.3 
papillomas per mouse (71% reduction; p = 0.02, t-test) (Fig. 
3A). The incidence of papillomas was remarkably varied among 
the groups. Wild-type and K5D3 mice developed visible tumors 
within 5–7 weeks of promotion, and they showed a 50% pen-
etrance by 8.5 and 9.5 weeks, respectively. Tumor development 
in cyclin D1-/- mice began at 10 weeks with a 50% penetrance by 
12.5 weeks. Notably, tumor development in K5D3/cyclin D1-/- 
mice was severely delayed, beginning at week 13 and reaching 
an incidence of 50% by week 16.5 (Fig. 3B). The size of the 
increased keratinocyte proliferation, we analyzed the BrdU incor-
poration in the interfollicular epidermis. Consistent with previ-
ous observations,30 we detected a 1.6-fold increase in the number 
of proliferative keratinocytes in the basal cell layer of K5D3 and 
K5D3/cyclin D1-/- compared with wild-type siblings (p < 0.0001, 
t-test) (Fig. 2C). It is worth noting that significant differences 
were not observed among the number of apoptotic cells in epider-
mis of the four genotypes analyzed (data no shown). Collectively, 
these findings suggest that the sole expression of cyclin D3 in 
mouse basal keratinocytes is sufficient to maintain epidermal 
homeostasis, including the interfollicular epidermis and hair 
follicles.
Reduced sensitivity to ras-dependent skin tumorigenesis 
upon simultaneous reduction of cyclin D1 and cyclin D2 protein 
Figure 3. Kinetics of papilloma formation and biochemical analysis of skin tumors. Wild-type (wt), 
K5D3, Cyclin D1-/- (D1-/-) and K5D3/D1-/- siblings were initiated with DMBA and promoted with mul-
tiple applications of tPA on dorsal mouse skin. (A) Average number of papillomas per mouse (mul-
tiplicity) as a function of weeks of study. (B) Percentage of tumor-free mice as a function of weeks 
of study (incidence). (C) Immunoblot analysis of wild-type (wt), K5D3, D1-/- and K5D3/D1-/- papilloma 
lysates developed with antibodies against cyclin D1, cyclin D2, cyclin D3, CDK4 and CDK2. β-actin 
was used as the loading control. (D) Skin papillomas were classified according their volume and de-
picted as percentage of the total number of tumors for each genotype. (e) BrdU label index of im-
munostained paraffin-sections of papillomas from wild-type (wt), K5D3, cyclin D1-/- and K5D3/ D1-/-.
www.landesbioscience.com Cell Cycle 339
We conclude that the simultaneous downregulation of 
cyclin D1 and cyclin D2 enhances the tumor inhibition observed 
in cyclin D1-/- and K5D3 mice under conditions where ras is 
constitutively activated. These data underscore a role for the 
cyclin D3-cyclin D2 negative feedback loop as a tumor suppres-
sor mechanism that prevents ras-induced carcinogenesis.
Discussion
We have previously reported that overexpression and/or abla-
tion of D-type cyclins results in varied sensitivities to chemically 
induced mouse skin tumors.27,29,37,38 By using the two-stage carci-
nogenesis model, we provided genetic evidence that ras-mediated 
tumorigenesis depends on signaling pathways that act preferen-
tially through cyclin D1 and cyclin D2.29,31 In fact, the ablation 
of cyclin D1 and cyclin D2 results in a 75% and 45% reduction 
in the number of skin papillomas, respectively.29,31 Moreover, 
forced expression of cyclin D1 and cyclin D2 leads to an increased 
number of skin tumors and resistance to Ca2+-induced keratino-
cyte differentiation.27,29 In contrast, overexpression of cyclin D3 
in mouse keratinocytes decreased skin tumorigenesis, which 
is associated with downregulation of cyclin D2.29 Therefore, 
to test whether simultaneous downregulation of cyclin D1 
and cyclin D2 could potentiate the inhibition of skin tumori-
genesis, we developed a K5D3/cyclin D1-/- compound mouse. 
Biochemical analysis of mouse epidermis showed that, in accor-
dance with K5D3 mice,29 K5D3/cyclin D1-/- mice exhibit a sig-
nificant reduction of cyclin D2 protein level. Therefore, we used 
this model to study the consequences of simultaneous ablation 
and downregulation of cyclin D1 and cyclin D2 in normal kera-
tinocyte proliferation and tumor development. Notably, K5D3/
cyclin D1-/- mice showed a dramatic inhibition of skin tumor 
development compared with K5D3 and cyclin D1-/- mice. Even 
when the experiment was extended to 30 weeks of promotion, the 
inhibitory effect in the K5D3/cyclin D1-/- mice was exacerbated. 
These results support a role of ras signaling acting through both 
cyclin D1 and cyclin D2 but not through cyclin D3 in skin tumor-
igenesis. This is consistent with our previous results establishing 
that skin tumor development is only restored in K5D3 mice after 
restitution of cyclin D2 levels in K5D3/K5D2 double transgenic 
mice.29 Supporting these data, we have previously reported that 
cyclin D1 and cyclin D2 are overexpressed in skin papillomas of 
tumors also varied among the genotypes. Wild-type papillomas 
were the largest, reaching of up to 300 mm3. Conversely, the 
K5D3/cyclin D1-/- papillomas were much smaller than the other 
groups, and 63% of the tumors never reached a volume of 30 
mm3 (Fig. 3D). The tumor size of the cyclin D1-/- and K5D3 
animals was between the size of the wild-type and the K5D3/
cyclin D1-/- papillomas (Fig. 3D). Together, these results indicate 
that although cyclin D3 can compensate for the lack of cyclin D1 
and cyclin D2 in normal epidermis homeostasis, it is not suffi-
cient to drive skin tumor development.
Biochemical analysis of D-type cyclin levels in papillomas 
demonstrated that cyclin D2 remained downregulated in tumors 
obtained from K5D3 and K5D3/cyclin D1-/- mice (4- and 5-fold 
reduction compared with wild-type mice, respectively) (Fig. 3C).
Therefore, to understand how the D-type cyclin levels affect 
keratinocyte proliferation, we quantified the BrdU incorporation 
in skin papillomas collected at 24 weeks after the initiation of 
oncogenic promotion. The number of proliferating BrdU+ cells 
were significantly reduced in cyclin D1-/- papillomas compared 
with the wild-type cohort (3-fold reduction, p < 0.0001, t-test) 
(Fig. 3E). Notably, overexpression of cyclin D3 appeared to com-
pensate for the lack of cyclin D1, as K5D3/cyclin D1-/- exhibited 
a comparable number of proliferative keratinocytes as shown by 
wild-type and K5D3 tumors (Fig. 3E). Importantly, very few 
apoptotic cells could be visualized by TUNEL staining, and 
their numbers were similar among the four genotypes analyzed 
(data not shown). Typically, DMBA application induces tumor 
initiation by inducing an activating mutation in codon 61 of the 
Ha-ras gene.36 To test whether the downregulation of D-type 
cyclins result in papilloma development by an alternative path-
way that was independent of ras, we characterized the spectrum 
of codon 61 Ha-ras mutation in skin tumors. Mutational analysis 
of tumors collected at 20 weeks of oncogenic promotion showed 
the presence of Ha-ras mutation in all tumors of the four geno-
types analyzed. Therefore, we concluded that tumor develop-
ment in cyclin D1-/- and K5D3/cyclin D1-/- animals depends on 
an Ha-ras mutation as the initiating event.
We evaluated the histopathological features of papillomas at 
24 weeks of oncogenic promotion, taking into account dysplas-
tic and anaplastic changes, including disturbed cell polarity, 
differentiation, abnormal mitosis, nuclear hyperchromatism 
and the nuclear/cytoplasmic ratio. Fifty percent of the wild-
type and K5D3 tumors were classified as regular papillomas, 
whereas the other 50% were classified as well-differentiated 
squamous cell carcinomas (SCC) with expansion of the basal 
and spinous layers, loss of polarity and cords of epidermal cells 
that were contiguous to the basal layer invading the dermis. In 
contrast, 100% of cyclin D1-/- and K5D3/cyclin D1-/- tumors 
were classified as well as differentiated papillomas with basal 
cell hyperplasia, mild acanthosis and hyperkeratosis, but they 
showed no invasion of epidermal cells into the dermis (Table 1). 
These results suggest that ablation of cyclin D1 and simultane-
ous ablation of cyclin D1/downregulation of cyclin D2 results 
in the development of benign tumors (well-differentiated papil-
lomas) compared with the malignant progression observed in 
wild-type tumors.
Table 1. Histopathological analysis of skin tumors
Mice
No of tumors/ 
group
No (%) of tumors classified as:
Papillomaa SCCb
Wild type 16 8 (50) 8 (50)
K5D3 12 6 (50) 6 (50)
Cyclin D1-/- 9 9 (100) 0 (0)
K5D3/Cyclin D1-/- 14 14 (100) 0 (0)
aNo atypia in basal layers, basal cell hyperplasia, mild acanthosis and 
hyperkeratosis and no invasion of epidermal cells into the dermis. 
bWell-differentiated SCC with expansion of basal and spinous layer, loss 
of polarity and cords of epidermal cells contiguous to the basal layer 
invading the dermis.
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was more notable in advanced stages of skin tumorigenesis.41,42 
Moreover, the kinetics of cyclin D1 overexpression coincide with 
the expression of the mutated Ha-ras allele.22 These results impli-
cate that functional differences among the three D-type cyclin 
exist in mouse epidermis, although the mechanisms involved in 
these variances have not yet been established.
The mechanism by which cyclin D3 expression represses 
cyclin D2 but not cyclin D1 remains unknown; although tran-
scriptional and post-translational mechanisms are likely to be 
involved.29 However, this negative feedback loop is specific for 
cyclin D3, because modifications in the levels of other D-type 
cyclins were not observed in K5-cyclin D1 and K5-cyclin D2 
transgenic mice.29,30 In addition, the role of cyclin D3 in cell pro-
liferation appears to be tissue-specific and controversial. In fact, 
cyclin D3 expression has been associated with terminal differen-
tiation in muscle cells and epithelium.18-20,43
Moreover, D-type cyclins, specifically cyclin D1, participate 
in pRb-independent pathways that may also be involved in the 
inhibition of cell proliferation and tumorigenesis. Furthermore, 
it has been recently reported that the reduction of cyclin D1 lev-
els in human cancer cells impairs the recruitment of RAD51 to 
damaged DNA, affecting DNA repair.44 In addition, a genetic-
proteomic screen has revealed that cyclin D1 plays a transcrip-
tional role during development.45
In summary, we developed a new animal model to study 
the effect of simultaneous downregulation of cyclin D1 and 
cyclin D2 in skin tumorigenesis. It is important to note that 
cyclin D1/cyclin D2 double-knockout mice were developed by 
the Sicinski group, but these mice died within the first 3 weeks 
of life.5 To the best of our knowledge this is the first time that 
the simultaneous downregulation of two members of the D-type 
cyclin family has been assessed to determine their potential use 
in tumor inhibition. We demonstrated that epidermal keratino-
cytes tolerate proliferation with very low levels of cyclin D2 and 
cyclin D1, but skin tumor development is blocked at an early 
stage of tumorigenesis. Therefore, our study presents a potential 
use of the cyclin D3-cyclin D2 negative feedback loop and/or 
the simultaneous inhibition of cyclin D1 expression as a possible 
target for cancer therapies.
Materials and Methods
Experimental animals. The generation of the cyclin D1 knock-
out (cyclin D1-/-) and K5-cyclin D3 (K5D3) transgenic mice has 
been previously described in references 30 and 32. To generate 
K5D3/cyclin D1-/- compound mice, we crossed cyclin D1+/- and 
K5D3 mice. Subsequently the K5D3/cyclin D1+/- mice were 
mated with cyclin D1+/- siblings. The genotype of each mouse 
was screened by PCR.30,32
Two-stage carcinogenesis protocol. Twelve mice of each 
genotype were utilized for the two-stage carcinogenesis protocol, 
a number based on power calculation using a 2 x 2 Chi-square 
test. Carcinogenesis was initiated in three-week-old mice with 
a single topical application of DMBA (200 nMol in 200 μl of 
acetone) to the dorsal skin. Two weeks after DMBA initiation, 
TPA (6.8 nMol in 200 μl of acetone) was applied twice a week 
wild-type mice, whereas the levels of cyclin D3 remain constant 
compared with normal and hyperproliferative skin.21
Our results established a clear difference between the effect 
of cyclin D3 overexpression in papilloma development and 
keratinocyte proliferation. Lack of cyclin D1 reduces keratino-
cyte proliferation in epidermis and tumors, but overexpression 
of cyclin D3 (K5D3/cyclin D1-/-) returns the rate of prolifera-
tion to that of wild type in both epidermis and tumors. These 
observations suggest that individual or simultaneous ablation 
of cyclin D1 and downregulation of cyclin D2 is well-tolerated 
by keratinocytes. However, the reduced number of papillomas 
observed in the K5D3/cyclin D1-/- mice indicates that decreased 
levels of cyclin D1 and D2 affect an early stage of tumor devel-
opment by disturbing the initiation stage and/or the clonal 
expansion of Ha-ras-mutated keratinocytes. Although it is not 
clear why cyclin D3 overexpression (associated with cyclin D2 
downregulation) compensates for the absences of cyclin D1 and 
cyclin D2 in keratinocyte proliferation but not in skin tumor 
development, it is tempting to speculate that cyclin D1/D2 are 
essential for proliferation/expansion of the chemically initiated 
hair follicle stem cells. Therefore, understanding the differences 
between the cell cycle regulation in keratinocyte stem cells vs. 
normal keratinocytes should permit appreciation of how the 
expansion of initiated stem cells and normal keratinocyte prolif-
eration are differently affected by deregulation of D-type cyclin 
levels.
The analysis of tumor size shows that tumorigenesis is also 
affected during the growth stage (tumor promotion). In fact, 63% 
and 46% of K5D3/cyclin D1-/- and K5D3 papillomas are smaller 
than 30 mm3 and tumors > 300 mm3 were not observed in the 
K5D3/cyclin D1-/- compound mice. Conversely, wild-type mice 
develop a considerable number of tumors > 300 mm3. Analysis of 
apoptosis in skin tumors shows no significant differences among 
the four genotypes analyzed. Thus, mechanisms other than 
changes in the rate of proliferation or apoptosis are involved in 
the reduced size of tumors overexpressing cyclin D3, and this 
implication warrants further investigation. Histopathological 
analysis of skin tumors show no malignant progression of the 
K5D3/cyclin D1-/- and cyclin D1-/- tumors; instead, they were 
all classified as benign papillomas (Table 1). Notably, 50% of 
the K5D3 tumors showed areas of invasion and were classified 
as well-differentiated squamous cell carcinomas, similar to the 
wild-type tumors. Thus, it is conceivable that cyclin D3 expres-
sion behaves as an oncogene even when cyclin D2 level is reduced, 
but the simultaneous downregulation and ablation of cyclin D2 
and cyclin D1 abrogates the oncogenic function of cyclin D3. 
These results suggest that cyclin D1 plays a unique role during 
the malignant conversion to SCC, since overexpression of each 
D-type cyclin member can induce malignant progression to 
SCC,27,29 but only cyclin D1 seems to be essential to allow malig-
nant progression in wild-type and cyclin D3-overexpressing mice 
(Table 1). Therefore, it is possible that in the context of ras-medi-
ated tumorigenesis, skin tumors become “addicted” to cyclin D1 
expression, which is regulated by Ha-ras.39,40 Supporting this 
idea, early studies on skin tumorigenesis showed that cyclin D1 
is expressed in small incipient papillomas, but overexpression 
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[Hepes (pH 7.5), 150 mmol/L NaCl, 1 mmol EDTA, 25 mmol 





, 1 mmol/L DTT and 1 mmol/L PMSF] with precoated 
antibodies against CDK2, CDK4 and CDK6 for 2 h at 4°C. 
The beads were washed twice with NP-40 buffer and once with 





]. Subsequently, 30 μL of kinase buffer, 1 μg of 
pRb or histone H1 (Upstate Biotechnology Inc.) substrate, 5 μCi 
of [γ-32P] ATP (6,000 Ci/mmol), 1 mmol/L DTT and 5 μmol/L 
ATP were added to the bead pellet and incubated for 30 min at 
30°C. SDS sample buffer was added and each sample was boiled 
for 3 min to terminate the reaction and they were electrophoresed 
through polyacrylamide gels. The bands obtained by protein gel 
blot and the kinase assay were quantified using UNSCANT IT 
gel software for Windows.
Immunostaining. Epithelial cell proliferation was mea-
sured by intraperitoneal injection of 60 μg/g (body weight) of 
5-bromodeoxyuridine (BrdU) 30 min before the mice were sac-
rificed by CO
2
 asphyxiation. BrdU incorporation was detected 
by immunohistochemical staining of paraffin-embedded skin 
sections with a mouse anti-BrdU (ab-2) monoclonal antibody 
(Calbiochem; EMB Biosciences), biotin-conjugated anti-mouse 
antibody (Vector Laboratories) and the avidinbiotin Vectastain 
Elite peroxidase kit (Vector Laboratories) with diaminoben-
zidine as a chromogen. Apoptotic cells were identified by ter-
minal deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling assays with the FragEL DNA Fragmentation Detection 
Kit, Colorimetric-TdT enzyme (Calbiochem; EMB Biosciences) 
according to the manufacturer’s instructions. Counterstaining 
with methyl green allows for the quantification of normal and 
apoptotic cells. The numbers of apoptotic cells in the tumors 
were determined in sections of 250 μm2 with a reticule grid.
Statistical analysis. Statistical analysis was performed using 
GraphPad Prism 4 Software (GraphPad Software Inc.).
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to the dorsal skin of each mouse for 30 weeks, and papilloma 
development was tracked weekly. Papillomas 1 mm in diameter 
or larger were scored once a week. Multiplicity and incidence of 
tumor-bearing animals were compared among the four genotypes 
(K5D3, cyclin D1-/-, K5D3/cyclin D1-/- and wild-type mice) at 24 
weeks using the t-test.
Protein gel blotting and kinase assays. After the mice were 
sacrificed, the dorsal skins were treated with a depilatory agent 
for 1 min and washed with tap water. The epidermal tissue was 
scraped off with a razor blade, placed into homogenization buffer 
[50 mmol/L HEPES, pH 7.5, 150 mmol/L NaCl, 2.5 mmol/L 
EGTA, 1 mmol/L EDTA acid, 0.1% Tween 20, 1 mmol/L 
dithiothreitol, 0.1 mmol/L phenylmethylsulfonyl fluoride 
(PMSF), 0.2 U/ml of aprotinin, 10 mmol/L b-glycerophosphate, 
0.1 mmol/L sodium vanadate and 1 mmol/L NaF] and homog-
enized using a manual homogenizer. The epidermal homogenate 
was centrifuged at 14,000x g at 4°C to collect the supernatant, 
which was used directly for protein gel blotting analysis or stored 
at -80°C. Mouse skin and tumors were ground in homogeniza-
tion buffer [60 mM TRIS-HCl, pH 8.6, 5 mM ethylenediami-
netetraacetate (EDTA), 5 mM ethylene glycolbis(2-aminoethyl 
ether)-N,N,N0,N0-tetraacetic acid (EGTA), 300 mM sucrose, 
anti-protease and anti-phosphatase cocktails]. The homogenates 
were sonicated and centrifuged at 10,000x g for 10 min. The 
supernatants were collected and used directly for protein gel blot 
analysis. The protein concentration was measured with the Bio-
Rad protein assay system (Bio-Rad Laboratories). Protein lysates 
(30 μg from each sample) were electrophoresed through 12% 
acrylamide gels and electrophoretically transferred onto nitrocel-
lulose membranes. After blocking the membranes with 5% non-
fat powdered milk in Dulbecco PBS, they were incubated with 1 
μg/ml of specific antibodies. The following antibodies were used: 
polyclonal antibodies against cyclin D2 (M20), CDK4 (C22), 
CDK2 (M2), CDK6 (C21), (Santa Cruz Biotech) and mono-
clonal antibodies against cyclin D1 (DCS-6), cyclin D3 (Ab-1) 
(NeoMarkers) and CDK6 (DCS-83) (Santa Cruz Biotech). 
Incubation with secondary antibodies followed by exposure to 
enhanced chemiluminescence (ECL detection kit; GE Health 
Care) was used for immunoblot detection.
To study the kinase activities, 500 μg of fresh protein was 
extracted and immunoprecipitated in tween-20 lysis buffer 
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